15 October 2019 – CannaPacific is pleased to announce the appointment of Dr Mike Fay to our team as our Chief Medical Officer. This extends his current role as an Executive Director. Mike brings impeccable credentials as the Chief Medical Officer, strengthening CannaPacific’s medical and product development team.
Mike completed his undergraduate degree of Medicine and Surgery at University of Otago 1993 and is currently completing his PhD on integrating advanced imagery into brain tumour treatment.
Conducting extensive research with a particular focus on brain tumours and the development of new imaging and treatment techniques, Mike is the principal investigator in a number of international cancer trials and collaborations with Canada, the UK and Germany. His research spans across several modalities including PET imagery, MRI imaging and developing multiplexed neuro-imaging techniques. Mike is a lead researcher in an NCIC trial into brain tumour treatment in elderly patients. A current research project centres on developing a new PET tracer for use in brain tumours.
Publishing extensively on both lung and neuro-oncology and alongside his commitment to research, Mike is a Senior Lecturer at the University of Queensland and a Conjoint Senior Lecturer at the University of Newcastle. He is also an active member of ASCO, ASTRO and COGNO and on the editorial board of The Journal of Translational Lung Cancer Research.
CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post traumatic stress disorder.
CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.
About medicinal cannabis:
Governments at both Commonwealth and State and Territory levels have implemented legislative and policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis products for patients in Australia. https://www.tga.gov.au/medicinal-cannabis-guidance-documents
Joshua Dennis (CEO)
Ph: 0427 631 611
Tim heads up the scientific operations of CannaPacific drawing experience from his recent role as the Head of Australian Operations and R&D for Sun Pharmaceutical Industries Australia’s Controlled Substances Division.
With over 35 years experience in the pharmaceutical industry, and 25 years in controlled substances as Site Director for Sun Pharma’s Controlled Substances as well as in Business Development, Operations and Quality, Tim is highly experienced in genomic-based molecular breeding of medicinal plants for the production of pharmaceutical actives
Tim’s professional qualifications include a Bachelor of Applied Science (Chemistry) from Central Queensland University; Master of Science Qualifier – Natural Products at Deakin University; and was made an Honorary Fellow from the University of Melbourne.
During his career Tim has led a major capital expansion program of over A$70million including a Fine Chemicals manufacturing plant (Finalist Australian Engineering Excellence Awards) and A$20million Natural product extraction facility.
Tim recently completed a stint as an Industrial Placement Fellow at the University of York overseeing a range of new technology projects applying Molecular biology and genetics to plant breeding for High Value Chemicals from Plants, large scale extraction technology as well as applications of Industrial Biotechnology in pharmaceutical actives manufacture.
CannaPacific is an Australian biotech company focused on the cannabinoid pharmaceutical sector. Licenced by the Australian Government to cultivate and research medicinal cannabis, CannaPacific has acquired an amazing 10,000 sqm Dutch glasshouse near Byron Bay, NSW to optimise the cultivation of medical cannabis to GACP & GMP Standards.
+61 427 631 611